Psychosocial and Neurocognitive Factors Associated With Hepatitis C - Implications for Future Health and Wellbeing

David Pires Barreira, Rui Tato Marinho, Manuel Bicho, Renata Fialho, Silvia Raquel Soares Ouakinin, David Pires Barreira, Rui Tato Marinho, Manuel Bicho, Renata Fialho, Silvia Raquel Soares Ouakinin

Abstract

Background: Hepatitis C virus (HCV) infection involves changes not only from the point of view of physical health, but also emotional, and social that have a significant impact on the quality of life of these patients. According to the literature review, it seems that there is an important association between psychosocial factors, in particular on a cognitive level and disease progression. The aim of this mini-review is to summarize recent literature looking at the associations between psychosocial and neurocognitive factors and HCV. Methods: PubMed/Medline was systematically searched for psychosocial and neurocognitive factors associated with hepatitis C, treatment adherence, and patient wellbeing. Results: Patients present with a range of extrahepatic symptoms including fatigue, anxiety, depression, and neurocognitive dysfunction. HCV's impact on quality of life and wellbeing has serious clinical and social implications. Conclusion: Hepatitis C and its management continue to have a profound impact on health and psychologic wellbeing. Considering the serious extrahepatic implications for individuals, it is imperative that healthcare professionals pay close attention to psychosocial and neurocognitive factors. The focus on combined clinical approaches could enhance understanding about the health and social impacts of hepatitis C along the life course.

Keywords: adherence; hepatitis C; neurocognition; psychosocial factors; wellbeing.

References

    1. Adinolfi L. E., Nevola R., Lus G., Restivo L., Guerrera B., Romano C., et al. (2015). Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J. Gastroenterol. 21 2269–2280. 10.3748/wjg.v21.i8.2269
    1. Adinolfi L. E., Nevola R., Rinaldi L., Romano C., Giordano M. (2017). Chronic hepatitis C virus infection and depression. Clin. Liver Dis. 21 517–534. 10.1016/j.cld.2017.03.007
    1. Alavi M., Grebely J., Matthews G. V., Petoumenos K., Yeung B., Day C., et al. (2012). Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection. J. Gastroenterol. Hepatol. 27 957–965. 10.1111/j.1440-1746.2011.07035.x
    1. Armstrong A. R., Herrmann S. E., Chassany O., Lalanne C., Da Silva M. H., Galano E., et al. (2016). The International development of PROQOL-HCV: an instrument to assess the health-related quality of life of patients treated for hepatitis C virus. BMC Infect. Dis. 16:443. 10.1186/s12879-016-1771-0
    1. Basseri B., Yamini D., Chee G., Enayati P. D. P., Tran T., Poordad F. (2010). Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 30 1012–1018. 10.1111/j.1478-3231.2010.02235.x
    1. Baune B. T., Air T. (2016). Clinical, functional, and biological correlates of cognitive dimensions in major depressive disorder – Rationale, design, and characteristics of the cognitive function and mood study (CoFaM-Study). Front. Psychiatry 7:150. 10.3389/fpsyt.2016.00150
    1. Bielski B. H. J., Chan P. C. (1976). Reevaluation of the kinetics of lactate dehydrogenase catalyzed chain oxidation of nicotinamide adenine dinucleotide by superoxide radicals in the presence of ethylenediaminetetraacetate. J. Biol. Chem. 251 3841–3844. 10.5812/hepatmon.8340
    1. Bladowska J., Zimny A., Kołtowska A., Szewczyk P., Knysz B., Gñsiorowski J., et al. (2013). Evaluation of metabolic changes within the normal appearing gray and white matters in neurologically asymptomatic HIV-1-positive and HCV-positive patients: magnetic resonance spectroscopy and immunologic correlation. Eur. J. Radiol. 82 686–692. 10.1016/j.ejrad.2012.11.029
    1. Boehmer K. R., Gionfriddo M. R., Rodriguez-Gutierrez R., Dabrh A. M. A., Leppin A. L., Hargraves I., et al. (2016). Patient capacity and constraints in the experience of chronic disease: a qualitative systematic review and thematic synthesis. BMC Fam. Pract. 17:127. 10.1186/s12875-016-0525-9
    1. Bogart L. M., Cowgill B. O., Kennedy D., Ryan G., Murphy D. A., Elijah J., et al. (2008). HIV-related stigma among people with HIV and their families: a qualitative analysis. AIDS Behav. 12 244–254. 10.1007/s10461-007-9231-x
    1. Boscarino J. A., Lu M., Moorman A. C., Gordon S. C., Rupp L. B., Spradling P. R., et al. (2015). Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS). Hepatology 61 802–811. 10.1002/hep.27422
    1. Butt G. (2008). Stigma in the context of hepatitis C: concept analysis. J. Adv. Nurs. 62 712–724. 10.1111/j.1365-2648.2008.04641.x
    1. Cacioppo J. T., Cacioppo S. (2014). Social relationships and health: the toxic effects of perceived social isolation. Soc. Pers. Psychol. Compass 8 58–72. 10.1111/spc3.12087
    1. Chasser Y., Kim A. Y., Freudenreich O. (2017). Hepatitis C treatment: clinical issues for psychiatrists in the post-interferon Era. Psychosomatics 58 1–10. 10.1016/j.psym.2016.09.004
    1. Cherner M., Letendre S., Heaton R. K., Durelle J., Marquie-Beck J., Gragg B., et al. (2005). Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64 1343–1347. 10.1212/01.WNL.0000158328.26897.0D
    1. Clifford D. B., Smurzynski M., Park L. S., Yeh T. M., Zhao Y., Blair L., et al. (2009). Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 73 309–314. 10.1212/WNL.0b013e3181af7a10
    1. Thames A. D., Castellon S. A., Singer E. J., Nagarajan R., Sarma M. al. (2015). Neuroimaging abnormalities, neurocognitive function, and fatigue in patients with hepatitis C. Neurol. Neuroimmunol. Neuroinflammation 2:e59. 10.1212/NXI.0000000000000059
    1. El Khoury A. C., Vietri J., Prajapati G. (2012). The burden of untreated hepatitis c virus infection: a US patients’ perspective. Dig. Dis. Sci. 57 2995–3003. 10.1007/s10620-012-2233-1
    1. Fava G. A., Cosci F., Sonino N. (2016). Current psychosomatic practice. Psychother. Psychosom. 86 13–30. 10.1159/000448856
    1. Feld J. J., Kowdley K. V., Coakley E., Sigal S., Nelson D. R., Crawford D., et al. (2014). Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370 1594–1603. 10.1056/NEJMoa1315722
    1. Ferri C., Ramos-Casals M., Zignego A. L., Arcaini L., Roccatello D., Antonelli A., et al. (2016). International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun. Rev. 15 1145–1160. 10.1016/j.autrev.2016.09.006
    1. Forton D. M., Allsop J. M., Main J., Foster G. R., Thomas H. C., Taylor-Robinson S. D. (2001). Evidence for a cerebral effect of the hepatitis C virus. Lancet 358 38–39. 10.1016/S0140-6736(00)05270-3
    1. Gaeta L., Di Palo M., Fasanaro A. M., Loguercio C. (2013). Cognitive dysfunctions in hepatitis C virus (HCV) infection. A mini review. Curr. Neurobiol. 4 43–46.
    1. Hilsabeck R. C., Perry W., Hassanein T. I. (2002). Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35 440–446. 10.1053/jhep.2002.31257
    1. Hong B. A., North C. S., Pollio D. E., Abbacchi A., Debold C., Adewuyi S. A., et al. (2011). The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion. J. Clin. Psychol. Med. Settings 18 99–107. 10.1007/s10880-011-9227-6
    1. Huckans M., Fuller B., Wheaton V., Jaehnert S., Ellis C., Kolessar M., et al. (2015). A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J. Psychosom. Res. 78 184–192. 10.1016/j.jpsychores.2014.07.020
    1. Iriana S., Curry M. P., Afdhal N. H. (2017). Neurologic manifestations of hepatitis C virus infection. Clin. Liver Dis. 21 535–542. 10.1016/j.cld.2017.03.008
    1. Kamaradova D., Latalova K., Prasko J., Kubinek R., Vrbova K., Mainerova B., et al. (2016). Connection between self-stigma, adherence to treatment, and discontinuation of medication. Patient Prefer. Adherence 10 1289–1298. 10.2147/PPA.S99136
    1. Kemp A. H. (2017). Editorial: mechanisms underpinning the link between emotion. Physical Health, and Longevity. Front. Psychol. 8:1338. 10.3389/fpsyg.2017.01338
    1. Kleinman L., Mannix S., Yuan Y., Kummer S., L’Italien G., Revicki D. (2012). Review of patient-reported outcome measures in chronic hepatitis C. Health Qual. Life Outcomes 10:92. 10.1186/1477-7525-10-92
    1. Kuhn T., Sayegh P., Jones J. D., Smith J., Sarma M. K., Ragin A., et al. (2017). Improvements in brain and behavior following eradication of hepatitis C. J. Neurovirol. 23 593–602. 10.1007/s13365-017-0533-0
    1. Lieveld F. I., van Vlerken L. G., Siersema P. D., van Erpecum K. J. (2013). Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann. Hepatol. 12 380–391.
    1. Lowry D., Burke T., Galvin Z., Ryan J. D., Russell J., Murphy A., et al. (2016). Is psychosocial and cognitive dysfunction misattributed to the virus in hepatitis C infection? Select psychosocial contributors identified. J. Viral Hepat. 23 584–595. 10.1111/jvh.12544
    1. Lowry D., Coughlan B., McCarthy O., Crowe J. (2010). Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J. Viral Hepat. 17 352–359. 10.1111/j.1365-2893.2009.01188.x
    1. Lucaciu L. A., Dumitrascu D. L. (2015). Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment. Ann. Gastroenterol. 28 440–447.
    1. Marinho R. T., Barreira D. P. (2013). Hepatitis C, stigma and cure. World J. Gastroenterol. 19 6703–6709. 10.3748/wjg.v19.i40.6703
    1. Mathes T., Antoine S.-L., Pieper D. (2014). Factors influencing adherence in Hepatitis-C infected patients: a systematic review. BMC Infect. Dis. 14:203. 10.1186/1471-2334-14-203
    1. McLachlan K. J. J., Gale C. R. (2018). The effects of psychological distress and its interaction with socioeconomic position on risk of developing four chronic diseases. J. Psychosom. Res. 109 79–85. 10.1016/j.jpsychores.2018.04.004
    1. Misselbrook D. (2014). W is for wellbeing and the WHO definition of health. Br. J. Gen. Pract. 64 582–582. 10.3399/bjgp14X682381
    1. Monaco S., Mariotto S., Ferrari S., Calabrese M., Zanusso G., Gajofatto A., et al. (2015). Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J. Gastroenterol. 21 11974–11983. 10.3748/wjg.v21.i42.11974
    1. Negro F., Forton D., Craxì A., Sulkowski M. S., Feld J. J., Manns M. P. (2015). Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 1345–1360. 10.1053/j.gastro.2015.08.035
    1. Okely J. A., Gale C. R. (2015). Well-being and chronic disease incidence: the english longitudinal study of ageing. Psychosom. Med. 78 335–344. 10.1097/PSY.0000000000000279
    1. Papadimitriou G. N. (2017). The “Biopsychosocial Model”: 40 years of application in Psychiatry. Psychiatriki 28 107–110. 10.22365/jpsych.2017.282.107
    1. Rohde D., Merriman N. A., Doyle F., Bennett K., Williams D., Hickey A. (2017). Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PLoS One 12:e0189339. 10.1371/journal.pone.0189339
    1. Schaefer M., Capuron L., Friebe A., Diez-Quevedo C., Robaeys G., Neri S., et al. (2012). Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J. Hepatol. 57 1379–1390. 10.1016/j.jhep.2012.07.037
    1. Smith D., Lovell J., Weller C., Kennedy B., Winbolt M., Young C., et al. (2017). A systematic review of medication nonadherence in persons with dementia or cognitive impairment. PLoS One 12:0170651. 10.1371/journal.pone.0170651
    1. Smith M. A., Chan J., Mohammad R. A. (2015). Ledipasvir-Sofosbuvir: interferon-/Ribavirin-free regimen for chronic hepatitis c virus infection. Ann. Pharmacother. 49 343–350. 10.1177/1060028014563952
    1. Steptoe A., Deaton A., Stone A. A. (2015). Psychological wellbeing, health and ageing. Lancet 385 640–648. 10.1016/S0140-6736(13)61489-0
    1. Treloar C., Rance J., Backmund M. (2013). Understanding barriers to hepatitis c virus care and stigmatization from a social perspective. Clin. Infect. Dis. 57(Suppl. 2), S51–S55. 10.1093/cid/cit263
    1. Valtorta N. K., Kanaan M., Gilbody S., Hanratty B. (2016). Loneliness, social isolation and social relationships: what are we measuring? A novel framework for classifying and comparing tools. BMJ Open 6:e010799. 10.1136/bmjopen-2015-010799
    1. Vere C.-C. (2009). Psychosocial stress and liver disease status. World J. Gastroenterol. 15:2980 10.3748/wjg.15.2980
    1. Vilhena E., Pais-Ribeiro J., Silva I., Pedro L., Meneses R. F., Cardoso H., et al. (2014). Psychosocial factors as predictors of quality of life in chronic portuguese patients. Health Qual. Life Outcomes 12:3. 10.1186/1477-7525-12-3
    1. Weiss J. J., Bräu N., Stivala A., Swan T., Fishbein D. (2009). Review article: adherence to medication for chronic hepatitis C-Building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol. Ther. 30 14–27. 10.1111/j.1365-2036.2009.04004.x
    1. Weissenborn K., Krause J., Bokemeyer M., Hecker H., Schüler A., Ennen J. C., et al. (2004). Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J. Hepatol. 41 845–851. 10.1016/j.jhep.2004.07.022
    1. WHO (1999). Report of a WHO consultation organized in collaboration with the viral hepatitis prevention. J. Viral Hepat. 6 35–47. 10.1046/j.1365-2893.1999.6120139.x
    1. Wiȩdłocha M., Marcinowicz P., Sokalla D., Stañczykiewicz B. (2017). The neuropsychiatric aspect of the HCV infection. Adv. Clin. Exp. Med. 26 167–175. 10.17219/acem/37787
    1. Yarlott L., Heald E., Forton D. (2017). Hepatitis C virus infection, and neurological and psychiatric disorders – A review. J. Adv. Res. 8 139–148. 10.1016/j.jare.2016.09.005
    1. Younossi Z., Henry L. (2015). Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol. Ther. 41 497–520. 10.1111/apt.13090
    1. Younossi Z., Kallman J., Kincaid J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology 45 806–816. 10.1002/hep.21565

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться